JP7446222B2 - 大きいサイズのイソキサゾリン粒子の調製方法 - Google Patents

大きいサイズのイソキサゾリン粒子の調製方法 Download PDF

Info

Publication number
JP7446222B2
JP7446222B2 JP2020524272A JP2020524272A JP7446222B2 JP 7446222 B2 JP7446222 B2 JP 7446222B2 JP 2020524272 A JP2020524272 A JP 2020524272A JP 2020524272 A JP2020524272 A JP 2020524272A JP 7446222 B2 JP7446222 B2 JP 7446222B2
Authority
JP
Japan
Prior art keywords
isoxazoline compound
particles
crystallization vessel
particle size
isoxazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501755A (ja
Inventor
ジョウ，ゲオルグ・エックス
コート，アーロン
シェンク，ルーク・ライアン
コイノフ，アサーナス
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2021501755A publication Critical patent/JP2021501755A/ja
Priority to JP2023180745A priority Critical patent/JP2024010042A/ja
Application granted granted Critical
Publication of JP7446222B2 publication Critical patent/JP7446222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
JP2020524272A 2017-11-07 2018-11-06 大きいサイズのイソキサゾリン粒子の調製方法 Active JP7446222B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023180745A JP2024010042A (ja) 2017-11-07 2023-10-20 大きいサイズのイソキサゾリン粒子の調製方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762582381P 2017-11-07 2017-11-07
US62/582,381 2017-11-07
US201762608904P 2017-12-21 2017-12-21
US62/608,904 2017-12-21
PCT/EP2018/080230 WO2019091940A1 (en) 2017-11-07 2018-11-06 Process for preparing large size isoxazoline particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023180745A Division JP2024010042A (ja) 2017-11-07 2023-10-20 大きいサイズのイソキサゾリン粒子の調製方法

Publications (2)

Publication Number Publication Date
JP2021501755A JP2021501755A (ja) 2021-01-21
JP7446222B2 true JP7446222B2 (ja) 2024-03-08

Family

ID=64172503

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524272A Active JP7446222B2 (ja) 2017-11-07 2018-11-06 大きいサイズのイソキサゾリン粒子の調製方法
JP2023070584A Active JP7578752B2 (ja) 2017-11-07 2023-04-24 注射可能なイソオキサゾリン医薬組成物および寄生生物の寄生に対するそれらの使用
JP2023180745A Pending JP2024010042A (ja) 2017-11-07 2023-10-20 大きいサイズのイソキサゾリン粒子の調製方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023070584A Active JP7578752B2 (ja) 2017-11-07 2023-04-24 注射可能なイソオキサゾリン医薬組成物および寄生生物の寄生に対するそれらの使用
JP2023180745A Pending JP2024010042A (ja) 2017-11-07 2023-10-20 大きいサイズのイソキサゾリン粒子の調製方法

Country Status (16)

Country Link
US (2) US11858904B2 (enExample)
EP (1) EP3707129A1 (enExample)
JP (3) JP7446222B2 (enExample)
KR (2) KR102819993B1 (enExample)
CN (1) CN111295375B (enExample)
AU (2) AU2018363686B2 (enExample)
BR (1) BR112020008848A2 (enExample)
CA (1) CA3081653A1 (enExample)
CL (1) CL2020001172A1 (enExample)
CO (1) CO2020006258A2 (enExample)
IL (1) IL274075A (enExample)
MX (3) MX2020004693A (enExample)
PE (1) PE20210170A1 (enExample)
PH (1) PH12020500586A1 (enExample)
UA (1) UA127892C2 (enExample)
WO (1) WO2019091940A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081646C (en) 2017-11-07 2024-03-19 Intervet International B.V. Injectable isoxazoline pharmaceutical compositions and uses thereof
MX2022007455A (es) 2019-12-18 2022-08-15 Elanco Tiergesundheit Ag Derivados de isoxazolina como plaguicidas.
AU2021277491B2 (en) 2020-05-20 2024-05-16 Intervet International B.V. Injectable pharmaceutical compositions and uses thereof
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
CN112724095A (zh) * 2020-09-25 2021-04-30 安徽省公众检验研究院有限公司 氟雷拉钠晶型及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005048A1 (ja) 2008-07-09 2010-01-14 日産化学工業株式会社 イソキサゾリン置換安息香酸アミド化合物の製造方法
JP2013528177A (ja) 2010-05-27 2013-07-08 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ４−［５−［３−クロロ−５−（トリフルオロメチル）フェニル］−４，５−ジヒドロ−５−（トリフルオロメチル）−３−イソオキサゾリル］−ｎ−［２−オキソ−２−［（２，２，２−トリフルオロエチル）アミノ］エチル］−１−ナフタレンカルボキサミドの結晶質形態
JP2014111578A (ja) 2012-11-01 2014-06-19 Sumitomo Chemical Co Ltd 外部寄生虫防除剤の投与方法
WO2014126208A1 (ja) 2013-02-14 2014-08-21 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物の結晶性多形体及びその製造方法
JP2015028006A (ja) 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4883296B2 (ja) 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
MX2009013748A (es) 2007-06-27 2010-01-26 Du Pont Metodo de control de plagas en animales.
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
ES2442342T3 (es) 2008-12-18 2014-02-11 Novartis Ag Derivados de las isoxazolinas y su uso como pesticida
BRPI0923009B1 (pt) 2008-12-19 2018-07-17 Elanco Tiergesundheit Ag compostos de isoxazolina, composição para o controle de parasitas e uso de compostos de isoxazolina para o preparo de composição para o controle de parasitas
CA2766291C (en) * 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
LT3052080T (lt) 2013-09-30 2025-08-25 Zoetis Services Llc Ilgo veikimo spiro-izoksazolino vaistinės formos
PL3082867T3 (pl) * 2013-12-20 2024-05-13 Intervet International B.V. Kompozycje izoksazoliny i ich zastosowanie w zapobieganiu lub leczeniu inwazji pasożytów u zwierząt
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
US20170020848A1 (en) 2015-04-08 2017-01-26 Merial Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
CA3081646C (en) 2017-11-07 2024-03-19 Intervet International B.V. Injectable isoxazoline pharmaceutical compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005048A1 (ja) 2008-07-09 2010-01-14 日産化学工業株式会社 イソキサゾリン置換安息香酸アミド化合物の製造方法
JP2013528177A (ja) 2010-05-27 2013-07-08 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ４−［５−［３−クロロ−５−（トリフルオロメチル）フェニル］−４，５−ジヒドロ−５−（トリフルオロメチル）−３−イソオキサゾリル］−ｎ−［２−オキソ−２−［（２，２，２−トリフルオロエチル）アミノ］エチル］−１−ナフタレンカルボキサミドの結晶質形態
JP2014111578A (ja) 2012-11-01 2014-06-19 Sumitomo Chemical Co Ltd 外部寄生虫防除剤の投与方法
WO2014126208A1 (ja) 2013-02-14 2014-08-21 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物の結晶性多形体及びその製造方法
JP2015028006A (ja) 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法

Also Published As

Publication number Publication date
KR20200085295A (ko) 2020-07-14
JP2021501755A (ja) 2021-01-21
US20240246921A1 (en) 2024-07-25
AU2024201160A1 (en) 2024-03-14
CN111295375B (zh) 2025-06-24
AU2018363686A1 (en) 2020-05-07
KR20240125076A (ko) 2024-08-19
JP2023099059A (ja) 2023-07-11
MX2025006001A (es) 2025-07-01
NZ765172A (en) 2024-05-31
JP2024010042A (ja) 2024-01-23
RU2020117583A3 (enExample) 2021-12-24
KR102819993B1 (ko) 2025-06-11
BR112020008848A2 (pt) 2020-10-20
EP3707129A1 (en) 2020-09-16
CO2020006258A2 (es) 2020-05-29
AU2018363686B2 (en) 2023-11-23
CL2020001172A1 (es) 2020-10-23
US20200331867A1 (en) 2020-10-22
IL274075A (en) 2020-06-30
CA3081653A1 (en) 2019-05-16
PH12020500586A1 (en) 2021-06-21
CN111295375A (zh) 2020-06-16
JP7578752B2 (ja) 2024-11-06
PE20210170A1 (es) 2021-01-29
RU2020117583A (ru) 2021-12-08
MX2023014279A (es) 2024-07-10
US11858904B2 (en) 2024-01-02
MX2020004693A (es) 2020-08-20
WO2019091940A1 (en) 2019-05-16
KR102694519B1 (ko) 2024-08-13
UA127892C2 (uk) 2024-02-07

Similar Documents

Publication Publication Date Title
JP7446222B2 (ja) 大きいサイズのイソキサゾリン粒子の調製方法
US8067423B2 (en) Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
CN100422143C (zh) 那格列奈b型结晶的制造方法
JP2024010042A5 (enExample)
JP2002518495A (ja) イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物
EP2709993A2 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
CN107698412A (zh) 基于气动雾化‑反溶剂结晶的炸药共晶体制备方法
JP2012087099A (ja) ナファモスタットメシル酸塩の晶析方法
JP2010511589A (ja) 静的条件下における溶液中の結晶成長
RU2797561C2 (ru) Способ получения частиц изоксазолина большого размера
EP3008055B1 (en) Tetrazolone derivatives
KR20140108222A (ko) 결정질 형태의 신속한 식별 및 제조를 위한 방법
KR101573616B1 (ko) 구아닐우레아 디니트라미드의 재결정에 의한 형상 및 입도 조절방법
CN105439980A (zh) 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN113278016B (zh) 一种小粒径阿齐沙坦的制备方法
KR20100102098A (ko) 결정질 화학요법제
KR20040000783A (ko) 직접 접촉 냉각 결정화법을 이용한 헥사나이트로스틸벤의재결정화 방법
KR102833486B1 (ko) 디하이드록실암모늄 5,5'-비스테트라졸-1,1'-디올레이트 재결정화 방법 및 그에 의해 재결정화된 tkx-50
TWI638810B (zh) 氘代咪唑酮化合物之晶型ｉ及其製備方法和用途
Rietveld et al. Navigating phase behaviour in pharmaceuticals to enable phases with desired properties
NZ805055A (en) Process for preparing large size isoxazoline particles
NZ765172B2 (en) Process for preparing large size isoxazoline particles
CN117263875A (zh) 一种戊唑醇晶体及其连续结晶方法和应用
JP2016065007A (ja) オルメサルタンメドキソミルの製造方法
SE416734B (sv) Forfarande for framstellning av i huvudsak kristallint, snabblosligt cefazolinnatrium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240227

R150 Certificate of patent or registration of utility model

Ref document number: 7446222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150